IL-22, but not IL-17, Dominant environment in cutaneous T-cell lymphoma

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7529-7538

  Miyagaki, Tomomitsu ^a   Sugaya, Makoto ^a   Suga, Hiraku ^a   Kamata, Masahiro ^a   Ohmatsu, Hanako ^a   Fujita, Hideki ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23P19; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CELL ISOLATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; EPIDERMIS HYPERPLASIA; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; SKIN BIOPSY; TH17 CELL; TH22 CELL; TUMOR MICROENVIRONMENT; VOLUNTEER;

ADULT; CHEMOKINE CCL20; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKINS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOSPHORYLATION; RECEPTORS, CCR6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84055222105     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1192     Document Type: Article

References (50)

1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Eng J Med 2004;350:1978-88. (Pubitemid 38580201)
2. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106. (Pubitemid 34073484)
3. Rajka G, Winkelmann RK. Atopic dermatitis and Sézary syndrome. Arch Dermatol 1984;120:83-4.
4. Martí RM, Estrach T, Reverter JC, Mascaró JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991;127:1511-6.
5. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996;132:42-7. (Pubitemid 26024809)
6. Van Haselen CW, Toonstra J, Preesman AH, Van Der Putte SC, Bruijnzeel-Koomen CA, Van Vloten WA. Sézary syndrome in a young man with severe atopic dermatitis. Br J Dermatol 1999;140:704-7. (Pubitemid 29191394)
7. Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous Tcell lymphoma and atopy: is there an association? Br J Dermatol 2003;149:1013-7. (Pubitemid 37541987)
8. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-41. (Pubitemid 32210037)
9. Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K, et al. Thymus and activation-regulated chemokine (TARC) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003;48:23-30. (Pubitemid 36091529)
10. Kagami S, Sugaya M, Minatani Y, Ohmatsu H, Kakinuma T, Fujita H, et al. Elevated serum CTACK levels in CTCL. J Invest Dermatol 2006;126:1189-91.
11. Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010;130:2304-11.
12. Sugaya M. Chemokines and cutaneous lymphoma. J Dermatol Sci 2010;59:81-5.
13. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006;18:349-56.
14. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218-22.
15. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008;181:5948-55.
16. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32. (Pubitemid 30408849)
17. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30. (Pubitemid 38076484)
18. Wolk K, Witte E, Wallace E,Döcke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-23.
19. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009;160:319-24.
20. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-83.
21. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83.
22. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003;111: 875-81. (Pubitemid 36470263)
23. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008;128:2625-30.
24. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7.
25. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009;123:59-66.
26. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123:2044-52.
27. Cirée A, Michel L, Camilleri-Bröet S, Jean Louis F, Oster M, Flageul B, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 2004;112: 113-20. (Pubitemid 39249498)
28. Chong BF, Wilson AJ, Gibson HM, Hafner MS, Luo Y, Hedgcock CJ, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008;14: 646-53. (Pubitemid 351231143)
29. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695-702. (Pubitemid 40354080)
30. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells. Nat Immunol 2009;10:857-63.
31. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-85.
32. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9. (Pubitemid 28452327)
33. Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hirakawa S, et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009;39:2779-88.
34. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41. (Pubitemid 41541791)
35. Kanda N, Koike S, Watanabe S. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 2005;116:1144-50. (Pubitemid 41571801)
36. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46. (Pubitemid 46785128)
37. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rötzschke O, Falk K.CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005;105:2877-86. (Pubitemid 40446282)
38. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 2003;121:1045-52. (Pubitemid 37430972)
39. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Aït-Yahia S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-86. (Pubitemid 28357765)
40. Dieu-NosjeanMC, Massacrier C,Homey B, Vanbervliet B, Pin JJ, Vicari A, et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192:705-18.
41. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002;99:2929-39. (Pubitemid 34525383)
42. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producingCD4+T cells lacking IL-17 production. Proc Natl Acad Sci USA 2009;106:21795-800.
43. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007;21:2512-8. (Pubitemid 350148895)
44. Rao V, Saunes M, Jørstad S, Moen T. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin Immunol 2009;133:303-13.
45. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3 +T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006;126:2217-23. (Pubitemid 44413168)
46. Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008;173:195-204. (Pubitemid 351947967)
47. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6. (Pubitemid 351521078)
48. Ishigame H, Kakuta S, Nagai T, Kadoki M,Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009;30:108-19.
49. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. JAMA 1992;267:1354-8.
50. Gambichler T, Skrygan M, Appelhans C, Tomi NS, Reinacher-Schick A, Altmeyer P, et al. Expression of human beta-defensins in patients with mycosis fungoides. Arch Dermatol Res 2007;299:221-4. (Pubitemid 46955880)